共 41 条
- [1] Treatment of Single and Multiple Food Allergies with ADP101: Results of the Harmony Phase 1/2 TrialJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB240 - AB240Petroni, DanielArcher, AmyWang, Mei-LunTuomi, LisaBradley, ShannonPiscia-Nichols, CheriDombkowski, AshleyMcClintock, Dana
- [2] The harmony trial: Baseline characteristics from a phase 1/2 trial of ADP101 for oral immunotherapy in children and adults with single or multiple food allergiesALLERGY, 2023, 78 : 9 - 10Gogate, S.Wang, M. L.Sullivan, A.Rabbee, N.Dombkowski, A.Mcclintock, D.
- [3] Incorporating the patient voice and patient engagement in GOAL-Hem: Advancing patient-centric hemophilia careRESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (01)Roberts, Jonathan C.Recht, MichaelGonzales, Sarah E.Stanley, JustinDenne, MichaelCaicedo, JorgeRockwood, Kenneth
- [4] EFFICACY AND SAFETY OF ADP101 MULTIFOOD ORAL IMMUNOTHERAPY IN FOOD-ALLERGIC PATIENTS IN THE HARMONY TRIALANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S65 - S65Carr, W.Archer, A.Bean, C.Wang, M.Levin-Young, O.Bradley, S.Tuomi, L.McClintock, D.
- [5] ADP101 simultaneous multi-food oral immunotherapy (mOIT) demonstrates clinically meaningful safety and efficacy with dose-dependent response in pediatric patients in the phase 1/2 harmony trialALLERGY, 2023, 78 : 276 - 277Kim, E.Archer, A.Wang, M. L.Sullivan, A.Rabbee, N.Dombkowski, A.Mcclintock, D.
- [6] Patient and public involvement and engagement in the development of innovative patient-centric early phase dose-finding trial designsResearch Involvement and Engagement, 10 (1)Alger E.Van Zyl M.Aiyegbusi O.L.Chuter D.Dean L.Minchom A.Yap C.
- [7] A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community BenefitBLOOD, 2023, 142Jonassaint, Charles R.Eppinger, Blaze ArmonFriend, DominiqueGreen, Golie LorenzoRobinson, MiaWoolford, TeonnaWyant, DeMitriousDavis, JanieOluyadi, AbdulafeezZaidi, Ahmar U.John, HollySmith, Wally R.
- [9] First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialNATURE MEDICINE, 2023, 29 (08) : 2079 - +Liu, Si-Yang MaggieTu, Hai-YanWei, Xue-WuYan, Hong-HongDong, Xiao-RongCui, Jiu-WeiZhou, ZhenXu, Chong-RuiZheng, Ming-YingLi, Yang-SiWang, ZhenBai, Xiao-YanLi, An-NaSun, Yue-LiHuang, JieLin, Jia-XinKe, E. E.Xu, Bing-FeiLu, ChangDu, YingyingChen, YuanMa, RuiWang, Bu-HaiCang, Shun-DongWang, Bin-ChaoChen, Hua-JunYang, Jin-JiLi, YangqiuZhou, QingWu, Yi-Long
- [10] First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialNature Medicine, 2023, 29 : 2079 - 2086Si-Yang Maggie LiuHai-Yan TuXue-Wu WeiHong-Hong YanXiao-Rong DongJiu-Wei CuiZhen ZhouChong-Rui XuMing-Ying ZhengYang-Si LiZhen WangXiao-Yan BaiAn-Na LiYue-Li SunJie HuangJia-Xin LinE. E. KeBing-Fei XuChang LuYingying DuYuan ChenRui MaBu-Hai WangShun-Dong CangBin-Chao WangHua-Jun ChenJin-Ji YangYangqiu LiQing ZhouYi-Long Wu